Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22441559 | 0.89 | POLB (0.35) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL1742367 | 0.82 | ALDH1A1 (0.39) | ALDH1A1POLB | |
| SCHEMBL26039054 | 0.82 | ALDH1A1 (0.39) | ALDH1A1POLB | |
| SCHEMBL27003067 | 0.82 | ALDH1A1 (0.39) | ALDH1A1POLB | |
| SCHEMBL8510561 | 0.82 | ALDH1A1 (0.39) | ALDH1A1POLB | |
| SCHEMBL9853482 | 0.80 | ALDH1A1 (0.37) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29587839 | 0.80 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL9853462 | 0.80 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL3237003 | 0.80 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL3240121 | 0.80 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| CN-103096893-B | Glycine transporter-1 inhibitor, Its Preparation Method And Use | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-05-04 | — | — | CN | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| CN-103096893-A | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RES INC | 2013-05-08 | — | — | CN | disclosed |
| EP-2575815-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-1465867-A1 | LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO | Neurocrine Biosciences, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030158209-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003031410-A1 | LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | ALDH1A1 1946/4885SMN1; SMN2 1389/4885POLB 1199/4885 |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | ALDH1A1 1946/4885SMN1; SMN2 1389/4885POLB 1199/4885 |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC6A5, SLC7A1, AGXT | ALDH1A1 1212/4885SMN1; SMN2 3096/4885POLB 4307/4885 |
| US-20030158209-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC4R | ALDH1A1 1900/4885SMN1; SMN2 3509/4885POLB 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.